The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Often clear skies this evening will allow for frost to develop. Low cloud will then roll in overnight, making the frost more localised.
Northampton Saints' Director of Rugby has denied that Wales international George North was knocked out during their game against Leicester.
Swansea defender Jordi Amat insists manager Bob Bradley has the backing of the players despite yesterday's 5-0 defeat to Tottenham.